Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aura Biosciences, Inc. (AURA : NSDQ)
 
 • Company Description   
Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 109

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.56 Daily Weekly Monthly
20 Day Moving Average: 231,072 shares
Shares Outstanding: 50.27 (millions)
Market Capitalization: $329.76 (millions)
Beta: 0.45
52 Week High: $12.38
52 Week Low: $4.35
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.54% 1.72%
12 Week 31.99% 10.73%
Year To Date -20.19% -25.25%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
80 GUEST STREET
-
BOSTON,MA 02135
USA
ph: 617-500-8864
fax: -
ir@aurabiosciences.com http://www.aurabiosciences.com
 
 • General Corporate Information   
Officers
Elisabet de los Pinos - Chief Executive Officer;President
David Johnson - Chairman of the Board of Directors
Amy Elazzouzi - Senior Vice President
Giovanni Mariggi - Director
Antony Mattessich - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 05153U107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 50.27
Most Recent Split Date: (:1)
Beta: 0.45
Market Capitalization: $329.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.12 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.57
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -37.50%
vs. Previous Quarter: -5.77%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -58.63
12/31/24 - -47.83
ROA
06/30/25 - -
03/31/25 - -49.74
12/31/24 - -41.33
Current Ratio
06/30/25 - -
03/31/25 - 11.06
12/31/24 - 10.77
Quick Ratio
06/30/25 - -
03/31/25 - 11.06
12/31/24 - 10.77
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.55
12/31/24 - 3.04
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©